CYP19A1 and breast carcinoma: Moreover, in a recent clinical study, initially designed to test the effect of denosumab on bone health in breast cancer patients receiving endocrine therapy (aromatase inhibitors), the recurrence of breast cancer was markedly reduced in the denosumab-treated group compared with the control group.